Verve Therapeutics Collaborates With Eli Lilly For Its Preclinical In Vivo Gene Editing Program Targeting Lipoprotein(a) For Atherosclerotic Cardiovascular Disease; Verve Will Receive $60M As Upfront & Equity Investment And $465M In Milestone Payments
Portfolio Pulse from Benzinga Newsdesk
Verve Therapeutics has partnered with Eli Lilly for its preclinical in vivo gene editing program targeting Lipoprotein(a) for atherosclerotic cardiovascular disease. Verve will receive $60M upfront and an equity investment, plus $465M in milestone payments.
June 15, 2023 | 10:34 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eli Lilly partners with Verve Therapeutics for a gene editing program targeting cardiovascular disease, investing $60M upfront and in equity, with potential $465M in milestone payments.
The partnership with Verve Therapeutics for the gene editing program targeting cardiovascular disease expands Eli Lilly's portfolio and strengthens its position in the market. The upfront and equity investment, along with potential milestone payments, indicate a strong commitment to the project, which could lead to positive outcomes for the company and its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Verve Therapeutics partners with Eli Lilly for its gene editing program targeting cardiovascular disease, receiving $60M upfront and an equity investment, plus $465M in milestone payments.
The partnership with Eli Lilly provides Verve Therapeutics with significant financial support for its gene editing program targeting cardiovascular disease. The $60M upfront and equity investment, along with the potential $465M in milestone payments, will help fund the program's development and could lead to positive outcomes for the company and its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100